In this article, we will discuss Paclitaxel (Dosage Overview). So, let’s get started.
Metastatic Breast Cancer
Paclitaxel (ABRAXANE) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically
Non-Small Cell Lung Cancer
Paclitaxel is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
Adenocarcinoma of the Pancreas
Paclitaxel (ABRAXANE) is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with
Closely monitor the infusion site for extravasation or drug infiltration during administration. Limiting the infusion of Paclitaxel to 30 minutes may reduce the risk of infusion-related reactions.
Consider premedication in patients who have had prior hypersensitivity reactions to Paclitaxel. Do not re-challenge patients who experience a severe hypersensitivity reaction to Paclitaxel.
Recommended Dosage for Metastatic Breast Cancer
After failure of combination chemotherapy for metastatic breast cancer or relapse within 6 months of adjuvant chemotherapy, the recommended regimen for Paclitaxel is 260 mg/m² administered intravenously over 30 minutes every 3 weeks.
Recommended Dosage for Non-Small Cell Lung Cancer
The recommended dose of ABRAXANE is 100 mg/m² administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Administer carboplatin on Day 1 of each 21-day cycle immediately after ABRAXANE
Recommended Dosage for Adenocarcinoma of the Pancreas
The recommended dose of ABRAXANE is 125 mg/m² administered as an intravenous infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle. Administer gemcitabine immediately after ABRAXANE on Days 1, 8, and 15 of each 28-day cycle.